Ligand discrimination in immune cells: Signal processing insights into immune dysfunction in ER+ breast cancer
PLOS Computational Biology · 2025
DOI: 10.1371/journal.pcbi.1013615 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS Computational Biology, 2025. Verfasst von Adina Matache und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Computational and Quantitative Medicine, Beckman Research Institute of City of Hope, Duarte, California, United States of America. Hauptthemen laut MEDLINE: Breast Neoplasms, Signal Transduction, Receptors, Estrogen. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, National Cancer Institute.
Abstract (Originalsprache)
Prior studies have shown that approximately 40% of estrogen receptor positive (ER+) breast cancer (BC) patients harbor immune signaling defects in their blood at diagnosis, and the presence of these defects predicts overall survival. Therefore, it is of interest to quantitatively characterize and measure signaling errors in immune signaling systems in these patients. Here we propose a novel approach combining communication theory and signal processing concepts to model ligand discrimination in immune cells in the peripheral blood. We use the model to measure the specificity of ligand discrimination in the presence of molecular noise by estimating the probability of error, which is the probability of making a wrong ligand identification. We apply our model to the JAK/STAT signaling pathway using high dimensional spectral flow cytometry measurements of transcription factors, including phosphorylated STATs and SMADs, in immune cells stimulated with several cytokines (IFNγ, IL-2, IL-6, IL-4, and IL-10) from 19 ER+ breast cancer patients and 32 healthy controls. In addition, we apply our model to 10 healthy donor samples treated with a clinically approved JAK1/2 inhibitor. Our results show reduced ligand identification accuracy and higher levels of molecular noise in BC patients as compared to healthy controls, which may indicate altered immune signaling and the potential for immune cell dysfunction in these patients. Moreover, the inhibition of JAK1/2 produces a unique pattern of signaling dysfunction, inducing increased ligand detection error rates and reduced signal-to-noise ratios for most immune cell subtypes. These results suggest a means to improve the use of signaling kinase inhibitor therapies by identifying patients with favorable ligand discrimination specificity profiles in their immune cells.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Computational and Quantitative Medicine, Beckman Research Institute of City of Hope, Duarte, California, United States of America.
- Department of Immuno-Oncology, Beckman Research Institute of City of Hope, Duarte, California, United States of America.
ORCID-Profile: Russell C Rockne
Förderung
- NCI NIH HHS
- National Cancer Institute
Zitieren
APA
Matache, A., Lima-Junior, J. R., Kuznetsov, M., Urbaniak, K., Branciamore, S., Rodin, A. S., Lee, P. P., & Rockne, R. C. (2025). Ligand discrimination in immune cells: Signal processing insights into immune dysfunction in ER+ breast cancer. PLOS Computational Biology. https://doi.org/10.1371/journal.pcbi.1013615
Vancouver
Matache A, Lima-Junior JR, Kuznetsov M, Urbaniak K, Branciamore S, Rodin AS, et al. Ligand discrimination in immune cells: Signal processing insights into immune dysfunction in ER+ breast cancer. PLOS Computational Biology. 2025. doi:10.1371/journal.pcbi.1013615
BibTeX
@article{Matache2025,
author = {Matache, Adina and Lima-Junior, Joao Rodrigues and Kuznetsov, Maxim and Urbaniak, Konstancja and Branciamore, Sergio and Rodin, Andrei S and Lee, Peter P and Rockne, Russell C},
title = {Ligand discrimination in immune cells: Signal processing insights into immune dysfunction in ER+ breast cancer},
journal = {PLOS Computational Biology},
year = {2025},
doi = {10.1371/journal.pcbi.1013615}
}
EUVIMED